Shahzad joined Advent in 1999 with a strong background in science, clinical medicine, and international finance.
He gained an MA in Physiological Sciences from Oxford University and an MD from Cambridge University, after which he specialised in interventional cardiology while also pursuing clinical and fundamental scientific research in heart muscle disorders.
Since joining Advent, Shahzad has been actively involved in over 30 portfolio companies in Europe and the USA in all sectors of Life Sciences, including Algeta, Respivert, Micromet, Biocartis, CardiAQ, Axonics Modulation Technologies, and MiroBio.
Shahzad currently serves on the Board of several portfolio Companies, including Orphalan, Moximed, Curve Therapeutics, and Proximie.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.